Cancer cells can develop various mechanisms to evade tumorspecific and non-specific
attacks in the TME of solid tumors. 2 Thus, systemic activation of immune systems or even …

Overexpression of the B7-H1 (PD-L1) molecule in the tumor microenvironment (TME) is a
major immune evasion mechanism in some patients with cancer, and antibody blockade of …

Immunomodulatory agents blocking the PD-1/PD-L1 pathway have shown a new way to
treat cancer. The explanation underlying the success of these agents may be the selective …

On March 5th, a novel immunosuppressive molecule, Siglec-15, was reported in Nature
Medicine by Professor Lieping Chen 1. Siglec-15 was reported in a wide variety of tumors …

Immune checkpoint blockade with programmed cell death (PD-1)/programmed death-ligand
1 (PD-L1) inhibitors has resulted in significant progress in the treatment of various cancer …

The ability of tumour cells to escape the surveillance and elimination by the immune system
represents one of the hallmarks of cancer. 1 2 This concept of immune control against …

Background The clinical benefit of immunotherapeutic approaches against cancer has been
well established although complete responses are only observed in a minority of patients …

Drugs targeting immune checkpoint molecules such as CTLA-4, PD-1, and PD-L1 are being
heralded as a breakthrough in oncology. However,“breakthrough” is a misnomer belying …

Tumors have developed multiple immunosuppressive mechanisms to turn down the innate
and the effector arms of the immune system, thus compromising most of the …

Immune checkpoint inhibitors (ICIs), including anti-PD-1 and anti-CTLA-4 therapeutic
agents, are now approved by the Food and Drug Administration for treatment of various …